Fosun Pharma’s Q3 net profit increased by 41.62% year-on-yea...

Fosun Pharma’s Q3 net profit increased by 41.62% year-on-year, and a total of 9.7 million doses of the mRNA new crown vaccine Fubitai® were administered

$FOSUN PHARMA (02196.HK)$ Fosun Pharma (02196.HK) yesterday disclosed the third quarterly report data, Q3 company revenue was 10.095 billion yuan, a year-on-year increase of 25.03%; net profit was 1.082 billion yuan, a year-on-year increase of 41.62%.

The growth of Fosun Pharma’s performance is due to alleviation of the pressure of centralized procurement and price reduction of stock varieties. According to the announcement, as of October 24, Fosun Pharma’s Fubitai (mRNA Covid-19 vaccine) has been vaccinated in Hong Kong, Macau and Taiwan over 9.7 million. Agent.

Article excerpted from the U.S. Stock Intelligence Agency